Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia

International Journal of Cancer

Volumn 129, Issue 10, 2011, Pages 2512-2521

  Ikezoe, Takayuki ^a   Kojima, Shinsuke ^a   Furihata, Mutsuo ^a   Yang, Jing ^a   Nishioka, Chie ^a,b   Takeuchi, Asako ^a   Isaka, Mayuka ^a   Koeffler, H Phillip ^c,d   Yokoyama, Akihito ^a  

^a KOCHI UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Singapore   (Singapore)

Author keywords

AML; AZ960; JAK2; STAT

Indexed keywords

ACLARUBICIN; ANTILEUKEMIC AGENT; AZ 960; CASPASE 3; CYTARABINE; DAUNORUBICIN; ENOCITABINE; IDARUBICIN; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; PROTEIN BCL XL; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL CLONE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN TARGETING; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; AMINOPYRIDINES; ANTIGENS, CD34; BONE MARROW; FEMALE; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROGNOSIS; PYRAZOLES;

EID: 80052965503     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25910     Document Type: Article

References (30)

1. Bonnet, D., Dick, JE,. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7. (Pubitemid 27298715)
2. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP,. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol 1989; 7: 1260-7. (Pubitemid 19220127)
3. Wells RJ, Woods WG, Buckley JD, Odom LF, Benjamin D, Bernstein I, Betcher D, Feig S, Kim T, Ruymann F, Smithson W, Srivastava S, et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study. J Clin Oncol 1994; 12: 2367-77. (Pubitemid 24346709)
4. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, Lioure B, Lamy T, Desablens B, Guilhot F, Caillot D, Abgrall JF, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997; 90: 2978-86. (Pubitemid 27444191)
5. Yamaoka K, Saharinen P, Pesu M, Holt VE, 3rd, Silvennoinen O, O'Shea JJ,. The Janus kinases (Jaks). Genome Biol 2004; 5: 253-8.
6. Yu H, Jove R,. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105. (Pubitemid 38198738)
7. Baker SJ, Rane SG, Reddy EP,. Hematopoietic cytokine receptor signaling. Oncogene 2007; 26: 6724-37. (Pubitemid 47585098)
8. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-8. (Pubitemid 40663494)
9. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL,. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652-60. (Pubitemid 44316134)
10. Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA,. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006; 1: e18
11. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG,. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274-81. (Pubitemid 43801351)
12. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, Tasian SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009; 106: 9414-8.
13. Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse JF, Capiod JC, Delobel J, Weber-Nordt R, Dusanter-Fourt I, Dreyfus F, Groner B, Prin L,. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996; 87: 1692-7. (Pubitemid 26068885)
14. Spiekermann K, Biethahn S, Wilde S, Hiddemann W, Alves F,. Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol 2001; 67: 63-71. (Pubitemid 33010380)
15. Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, DeWald GW, Kaufmann SH,. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006; 20: 971-8. (Pubitemid 43797287)
16. Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, Vandenberghe EA, Winship PR, Reilly JT,. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000; 111: 190-5.
17. Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, Koeffler HP, Taguchi H,. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 2006; 5: 2522-30. (Pubitemid 44650916)
18. Gozgit JM, Bebernitz G, Patil P, Ye M, Parmentier J, Wu J, Su N, Wang T, Ioannidis S, Davies A, Huszar D, Zinda M,. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem 2008; 283: 32334-43.
19. Ikezoe T, Takeuchi T, Yang J, Adachi Y, Nishioka C, Furihata M, Koeffler HP, Yokoyama A,. Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest 2009; 89: 1364-73.
20. Nishioka C, Ikezoe T, Yang J, Miwa A, Tasaka T, Kuwayama Y, Togitani K, Koeffler HP, Yokoyama A,. Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo. Blood 2008; 111: 5086-92.
21. Hanley JA, McNeil BJ,. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36. (Pubitemid 12142173)
22. Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E,. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000; 95: 3765-70. (Pubitemid 30412848)
23. Dawson MA, Bannister AJ, Göttgens B, Foster SD, Bartke T, Green AR, Kouzarides T,. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009; 461: 819-22.
24. McCormack MP, Rabbitts TH,. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004; 350: 913-22. (Pubitemid 38252539)
25. Yamada Y,., Pannell R, Forster A, Rabbitts TH,. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci USA 1998; 95: 3890-5. (Pubitemid 28173224)
26. Birkenkamp KU, Geugien M, Lemmink HH, Kruijer W, Vellenga E,. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 2001; 15: 1923-31. (Pubitemid 33115000)
27. Kato Y, Iwama A, Tadokoro Y, Shimoda K, Minoguchi M, Akira S, Tanaka M, Miyajima A, Kitamura T, Nakauchi H,. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med 2005; 202: 169-79. (Pubitemid 41002919)
28. Wang Z, Li G, Tse W, Bunting KD,. Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood 2009; 113: 4856-65.
29. Pardanani AD, Gotlib JR, Jamieson C, Cortes J, Talpaz M, Stone R, Silverman MH, Gilliland DG, Shorr J, Tefferi A,. Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. J Clin Oncol. 2011 Jan 10. [Epub ahead of print].
30. Ravandi F, Verstovsek S, Estrov Z, Burger JA, George S, Bivins C, Cortes-Franco J, Garrett W, Newton R, Kantarjian H,. Significant activity of the JAK2 inhibitor, INCB018424 in patients with secondary, postmyeloproliferative disorder acute myeloid leukemia: results of an exploratory phase II study. Blood. (ASH Annual Meeting Abstracts). 2009; 114: 261-262 (#631).